Kronos Bio : Management Change/Compensation
Kron-20230622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054...
Source: marketscreener.com
Page 10 - Kronos Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kronos Bio Today - Breaking & Trending Today
Lurbinectedin Plus Doxorubicin Shows Early Efficacy and Safety in Soft Tissue Sarcomas
A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.
Source: onclive.com
DelveInsight Business Research, LLP: CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus
The dynamics of the CDKL5 deficiency disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases
Source: finanznachrichten.de
Kronos Bio Announces Participation in Upcoming Investor Conferences
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 -- Kronos Bio, Inc. , a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management... | June 1, 2023
Source: marketscreener.com
Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma
Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.
Source: onclive.com